Radiopharm Theranostics Ltd Ordinary Shares RAD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.05
- Day Range
- A$0.05–0.05
- 52-Week Range
- A$0.04–0.20
- Bid/Ask
- A$0.04 / A$0.05
- Market Cap
- A$20.78 Mil
- Volume/Avg
- 671,125 / 728,200
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
Valuation
|
Metric
|
RAD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.71 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RAD
|
|---|---|
Quick Ratio | 0.49 |
Current Ratio | 0.50 |
Interest Coverage | — |
Quick Ratio
RAD
Profitability
|
Metric
|
RAD
|
|---|---|
Return on Assets (Normalized) | −57.09% |
Return on Equity (Normalized) | −97.71% |
Return on Invested Capital (Normalized) | −96.65% |
Return on Assets
RAD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qbwqlbxwfw | Ggwc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ccmtcmkh | Knlddzg | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rmyvfmb | Fqpvhrc | $97.8 Bil | |
MRNA
| Moderna Inc | Ddmvbvhv | Zfvn | $41.3 Bil | |
ARGX
| argenx SE ADR | Zjnrxshyz | Dfg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pstssfjp | Yfmk | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mynktbp | Hrpnyk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kszsthtp | Jdgyk | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Grdzjtfkw | Hxyvcbj | $12.5 Bil | |
INCY
| Incyte Corp | Xtjsdyls | Tsvhjc | $11.6 Bil |